When a Broken Market Grows at 8,168 Percent

The strange thing about broken systems

What does it mean when a market becomes so dysfunctional that the businesses selling relief from it grow at extraordinary speed? That question sits at the center of modern drug pricing. On one side is a system so opaque and fragmented that even sophisticated buyers struggle to see where the money goes. On the other side are new platforms promising alignment, transparency, and control, and some of them are scaling at breathtaking rates.

The paradox is simple: the more broken a market becomes, the more valuable clarity becomes. But clarity is not free. It must compete against entrenched incentives, hidden fees, and institutions that profit from complexity. In prescription drugs, that tension is not abstract. It affects what patients pay at the pharmacy counter, what employers budget for benefits, and what middlemen can extract from the gap between the two.

The deeper question is not whether the system is expensive. It is why expensive systems can persist for so long, and why, once they become too opaque to justify, entirely new categories of companies suddenly become possible.

---

Opaqueness is not a bug, it is the business model

In healthy markets, price and value tend to move toward one another. If a buyer can compare options, a seller must compete on something real: quality, reliability, service, or cost. Prescription drug benefits often fail that test because the buyer rarely sees the full chain of incentives. Employers, plans, pharmacies, drug manufacturers, and intermediaries all touch the transaction, but no single party always sees the whole picture.

That is where pharmacy benefit managers became central. In theory, they negotiate lower drug costs and manage formularies, rebates, and networks. In practice, the very design of the role can reward complexity. If compensation is tied to spread, rebate flows, administrative arrangements, or opaque contracting structures, then the system does not merely tolerate confusion. It may actively produce it.

Think of a restaurant where the menu lists one price, the kitchen charges a second, the server pockets a third, and the customer only sees the bill after eating. That is not a pricing model. It is an information asymmetry with a payment terminal attached.

When the rules of a market make it hard to know who is paying whom, opacity becomes a revenue stream.

That is why scrutiny of drug intermediaries matters so much. The debate is not only about whether they are useful. It is about whether their usefulness depends on keeping the true economics hidden from the people financing the system.

---

The fastest growing companies in broken markets do not just sell software

When a company grows explosively in a troubled industry, it is tempting to treat the growth as a standard tech story: better product, stronger sales, bigger market. But in a broken market, growth often means something more interesting. It means the company has found a way to convert dissatisfaction into infrastructure.

That is especially true in pharmacy benefits. A platform that promises an aligned PBM model is not merely a nicer interface. It is a challenge to the old architecture of incentives. By offering an enterprise pharmacy platform that integrates the administration, adjudication, and oversight of benefits, it attempts to replace scattered, opaque processes with a single system of record and accountability.

This matters because the real product is not just a service. It is legibility. The buyer wants to know what drugs cost, why they cost that much, which parties are taking margin, and what levers can actually reduce spend without hurting patients. If the platform can make those answers visible, it can become the operating system for a category that previously behaved like a maze.

The explosion in growth is therefore revealing. It suggests that the market is not simply adopting a new tool. It is voting against a prior way of doing business.

---

The real contest is between extraction and coordination

At first glance, the fight over drug benefits looks like a fight over prices. But underneath it is a deeper contest between two economic logics.

The first logic is extraction. Each participant tries to maximize its take from the transaction while preserving enough ambiguity to keep the system running. The goal is not necessarily to deliver the best end outcome for the purchaser or patient. The goal is to control a flow of money that is hard to trace.

The second logic is coordination. Here, the goal is to make the chain of decisions simpler, more transparent, and more aligned with the actual payer’s interests. Coordination does not eliminate profit. It changes how profit is earned. Instead of profiting from hidden spread or fragmented accountability, the business profits by reducing waste, improving decisions, and making costs predictable.

This distinction is important because many market observers mistake complexity for sophistication. They are not the same. A system can have many moving parts and still be badly coordinated. In fact, the more pieces there are, the easier it is for each one to claim necessity while hiding its impact on the whole.

A useful mental model is to compare two maps. One map is cluttered with every road, toll booth, and side street, but no one can tell where the destination is. The other map is simpler, with fewer layers and clearer routes. The first map may look more detailed, but the second is more useful. In drug benefits, the most valuable innovation may not be added complexity. It may be the removal of unnecessary opacity.

---

Why the system rewards middlemen until it suddenly punishes them

Most opaque markets survive because their hidden costs are diffuse. No single buyer feels the full pain, and no single seller bears the full blame. Employers absorb rising premiums over time. Patients encounter surprise costs in moments of vulnerability. Manufacturers focus on their own pricing strategies. Intermediaries harvest incremental gains at many touchpoints.

This arrangement can persist for years because the cost of investigation is high and the payoff is uncertain. But once one actor proves that it is possible to make the economics visible and control them more directly, the old system becomes fragile. What once looked inevitable starts to look like rent extraction.

That is why rapid growth in transparency oriented models is so disruptive. It lowers the switching cost of disbelief. Buyers who once assumed the existing PBM structure was unavoidable can now imagine alternatives. And once imagination changes, procurement changes too.

This is a familiar pattern in other industries. Cloud software did not just digitize paper workflows. It redefined what was normal. Ride sharing did not merely improve taxi dispatch. It changed expectations around location, pricing, and convenience. In the same way, a modern pharmacy platform can do more than reduce administrative burden. It can reset the baseline for what a benefit manager is supposed to be.

---

The hidden value of alignment

The word alignment can sound bland, but in a market like this, it is revolutionary. Alignment means the people making decisions are rewarded for outcomes the payer actually wants: lower net cost, clearer data, fewer surprise bills, and better adherence to clinically appropriate therapy.

This is powerful because it changes the unit of success. In a misaligned system, success might mean larger rebate pools, wider spreads, or more claims volume. In an aligned system, success means the employer or plan can understand total cost and control it with confidence.

Alignment also changes organizational behavior inside the buyer. When finance, HR, procurement, and benefits teams can all see the same data, they can stop treating drug spend as an unavoidable black box. They can ask better questions:

• Why does this drug cost more here than elsewhere?
• Which rebate is real savings, and which is accounting theater?
• What portion of our spend is driven by utilization, and what portion is driven by contract design?
• Are we optimizing for headline discounts or for net cost after all fees?

These questions sound basic. In a distorted market, they are radical.

A transparent system does not just save money. It gives organizations the right questions to ask.

That may be the most underappreciated benefit of modern benefits infrastructure. Better data is not only a reporting upgrade. It is a governance upgrade.

---

A framework for understanding the transition

The shift from opaque intermediaries to aligned platforms can be understood through three stages.

1. Complexity as shelter

In the first stage, complexity protects incumbents. The market is too hard to audit, too hard to benchmark, and too hard to challenge. Each participant can defend its role as indispensable.

2. Legibility as leverage

In the second stage, a new entrant makes the system readable. It does not need to solve every problem at once. It only needs to make costs, incentives, and decisions visible enough that buyers can compare reality to rhetoric.

3. Alignment as product

In the third stage, transparency becomes embedded in operations. The platform is no longer an analytics layer sitting on top of a broken system. It becomes the system itself, designed so that incentives, administration, and outcomes point in the same direction.

This framework explains why a company can grow so quickly in a heavily criticized sector. It is not just selling efficiency. It is selling a migration path from one economic regime to another.

---

What this means for buyers, operators, and policymakers

If a market’s biggest problem is opacity, then the first mistake is usually to ask for better slogans instead of better structure. Buyers often negotiate for lower headline prices, then discover that the hidden fees, spread pricing, formulary games, or rebate mechanics eat up the savings. The better question is whether the contract changes the underlying incentives.

Operators should think in terms of control points. Where does the money enter the system? Who has discretion? Who sees the data? Who can audit outcomes? The most useful reforms often do not require a total redesign. They require placing transparency at the points where value leaks.

Policymakers, meanwhile, should recognize that not all intermediaries are the same. Some intermediaries create genuine scale, risk pooling, or administrative simplicity. Others monetize the lack of visibility. The policy challenge is not to eliminate every middle layer. It is to distinguish between coordination layers and rent collection layers.

A practical test is simple: if a participant cannot explain how it is paid in language a sophisticated buyer can understand, the burden should not be on the buyer to trust the mystery.

---

Key Takeaways

1. In opaque markets, complexity itself can become a profit center. If the buyer cannot see the full economics, incentives drift away from value creation and toward extraction.

2. Fast growth in a broken market often signals a shift in market structure, not just product quality. Buyers are not merely adopting software. They are rejecting an old operating model.

3. Alignment is not a soft concept. In pharmacy benefits, it is the difference between a system that rewards hidden margin and one that rewards lower net cost and better decisions.

4. Transparency is a governance tool, not just a reporting feature. When buyers can see costs and incentives clearly, they can ask better questions and negotiate from a position of strength.

5. The best fixes often simplify the system rather than decorate it. The goal is not more layers of management. It is fewer places for value to disappear.

---

The market is voting for legibility

The deepest lesson here is that many people do not actually want a more complicated solution to a complicated problem. They want a system they can understand, audit, and trust. In prescription drug benefits, that desire has enormous economic force because the status quo is not merely expensive. It is hard to explain.

That is why the rise of aligned platforms is so significant. It reflects a broader market judgment: the future belongs to systems that make hidden costs visible and hidden incentives accountable. Once a market reaches the point where people cannot tell whether the middleman is helping or harvesting, the demand for legibility becomes unstoppable.

So the real story is not that a company grew very fast. The real story is that a market built on obscurity is now being forced to answer a simple question: if you need darkness to function, how long can you last once someone turns on the lights?